Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company’s EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.